Safety and tolerability results from the decide study: A phase 3 active-comparator study of daclizumab HYP in relapsing-remitting multiple sclerosis

Authors
Category Primary study
JournalNeurology
Year 2015
This article has no abstract
Epistemonikos ID: 499a5154efd690d5327472d8fcb74d0f7d95b101
First added on: Feb 07, 2025